Figure 3.

Inhibition of NLRP3 inflammasome may have therapeutic potential for COVID-19 and related neurological syndromes. Graphical representation of inflammasome inhibition by various inhibitors. The NLRP3 inflammasome is a prospective target for therapeutic approaches in the treatment of COVID-19. Inhibitors against NLRP3 inflammasome may ameliorate SARS-CoV-2-induced hyperinflammation and related cytokine storms. These inhibitors, in addition to their beneficial effects in lung and other organs, could also have therapeutic potential for COVID-19 neurological syndromes associated with microglial NLRP3 inflammasome activation.